BioIVT to Present Advances in Immunohistochemistry at AAPS Annual Meeting


November 7, 2017

BioIVT will also showcase its expanded research services resulting from its Qualyst Transporter Solutions and Asterand Bioscience acquisitions earlier this year

BioIVT, a leading provider of biospecimens and related services, today announced that it will be presenting and exhibiting at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. This conference will be held from Nov. 12-15 at the San Diego Convention Center in San Diego, CA.

“BioIVT is proud to support AAPS, share our knowledge and experience, and help to support the next generation of pharmaceutical scientists. High content immunohistochemistry (IHC) is an exciting and rapidly-evolving field, and at BioIVT we are expanding our expertise and services to ensure that we continue to meet researchers’ growing needs,” said Dr. Amanda Woodrooffe, BioIVT vice president and general manager, UK.

“Since BioIVT acquired Qualyst and Asterand earlier this year, our research solutions have become increasingly comprehensive. They now include target and biomarker validation, ADMET, characterization of novel therapeutics, and the development of clinical assays. These value-added service offerings allow us to further characterize our normal and disease-state biospecimens, especially our hepatocyte and tissue products, to more precisely meet our customers’ needs,” Dr. Woodrooffe added.

Highlighting BioIVT’s commitment to developing new scientific solutions, Senior Scientist Richard Bystry will present “6 Into 1 Will Go – Advantages of Multiplexing IHC in Human Tissues” from 10:30-11:30 a.m. PT on Nov. 15.

Multiplex IHC is one of the most powerful tools in pre-clinical and clinical research because it allows single tissue sections to be immunostained multiple times. As a result, the location of immune and cancer cells, together with relevant checkpoint markers, can be determined in clinical responders and non-responders. This knowledge can assist in identifying treatment escape routes that cancer cells could take, and help to inform subject enrollment in clinical trials.

BioIVT will also have experts available to answer questions about its disease-state and control matrices, primary cell types, in vitro cell-based assays, target and biomarker validation and ADMET research services in booth #1322.

Further information about the AAPS Annual Meeting is available at


About BioIVT

BioIVT, formerly known as BioreclamationIVT, is a worldwide provider of biological products to the life sciences and pharmaceutical industries. The company specializes in control and disease-state matrices manufactured from human and animal biological specimens and has recently expanded its offering to include cell processing, target and biomarker validation, ADMET, phenotypic assays to characterize novel therapeutics and the development of clinical assays. As a premier supplier of ADME-toxicology model systems, BioIVT enables scientists and biomedical researchers to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes. BioIVT’s reputation for providing exceptional customer service coupled with the highest quality biospecimens and services have made it the first-choice supplier for more than 35 years. For more information, please visit or follow the company on Twitter @BiorecIVT.

Post a Comment

You must be logged in to post a Comment.